Invivyd (NASDAQ:IVVD) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Invivyd (NASDAQ:IVVD) announced its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.10, Zacks reports.

Invivyd Trading Up 11.4 %

Shares of IVVD traded up $0.08 during mid-day trading on Thursday, reaching $0.80. The company’s stock had a trading volume of 918,226 shares, compared to its average volume of 4,201,001. The stock has a market cap of $95.93 million, a PE ratio of -0.41 and a beta of 0.09. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The company’s fifty day moving average price is $0.97 and its two-hundred day moving average price is $0.87.

Analyst Ratings Changes

Several brokerages have commented on IVVD. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research report on Wednesday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Finally, Morgan Stanley lowered their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Invivyd currently has a consensus rating of “Buy” and a consensus price target of $7.89.

Insider Transactions at Invivyd

In related news, Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20. Following the completion of the sale, the director now directly owns 3,492,498 shares in the company, valued at $1,571,624.10. This represents a 2.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders sold 365,943 shares of company stock worth $171,220. 17.90% of the stock is currently owned by insiders.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.